Anteris Technologies extends manufacturing agreement with LeMaitre for CardioCel and VascuCel

Anteris Technologies signed a nine-month extension to its manufacturing contract with LeMaitre Vascular Inc. on August 30, 2021, to continue producing CardioCel and VascuCel at its Malaga facility in Western Australia until July 2023.

“This extension helps maximise the capacity utilization of our facility in Australia as we continue to manufacture.”listcorp.com

• 1 source
• listcorp.comExtended Manufacturing Agreement - Anteris Technologies Ltd (ASX:AVR) - Listcorp.Aug 29, 2021

Summarized from public sources; check the original articles before acting on it.